Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis 2015 Size and Forecast 2019

According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.

Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.
Covered in this Report
The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.
Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
Actavis PLC
Amgen Inc.
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Other Prominent Vendors
Abbott Laboratories
Akebia Therapeutics
AMAG Pharmaceuticals
Cara Therapeutics
Keryx Biopharmaceuticals
Reata Pharmaceuticals
OPKO Health
Raptor Pharmaceuticals
Regulus Therapeutics
Rockwell Medical
Shield Therapeutics
Takeda Pharmaceuticals
Vifor Pharma Ltd
Xenetic Biosciences
ZS Pharma

Market Driver
Increase in Associated Disorders with CKD
For a full, detailed list, view our report.
Market Challenge
Genericization of Major Brands
For a full, detailed list, view our report.
Market Trend
Approval of New Pipeline Drugs
For a full, detailed list, view our report.